What does “MSC therapy” actually mean?
MSC stands for mesenchymal stromal cell, also called mesenchymal stem cell. Researchers obtain these cells from tissues including bone marrow, fat and umbilical cord. The name covers a family of preparations, not one medicine with one predictable effect.
A landmark laboratory study showed that selected human marrow cells could become bone, cartilage and fat cells under particular culture conditions. That established biological potential. It did not demonstrate that injecting them into a person rebuilds those tissues. The later international definition specifies laboratory characteristics used to identify MSCs, rather than a clinical guarantee. 1999 laboratory study; ISCT definition.
This distinction is useful before reading any success story or trial: which cells, prepared how, given where, and for what condition? A marrow-derived infusion for a transplant complication and a cord-derived knee injection are different interventions.
How might they help?
MSCs can interact with immune cells and release signaling molecules. In laboratory and animal models, those interactions can change inflammation and tissue responses. A 2017 graft-versus-host disease study found that recipient immune cells killing the infused MSCs was part of the therapeutic mechanism in mice; observations in patients supported a related hypothesis. That is more complicated than cells simply traveling to damage and replacing what is missing. Mechanistic study.
The clinical mechanism is still not fully settled. Even the prescribing information for Ryoncil, an approved MSC product, says its mechanism of action is unclear and that it may involve immune modulation. A plausible mechanism helps explain why a treatment is worth testing. The trial still has to show whether people benefit. FDA prescribing information.
Where has a product earned approval?
In the United States, Ryoncil is an intravenous, donor-derived bone marrow MSC product for steroid-refractory acute graft-versus-host disease in children aged two months and older. This is a serious complication after a hematopoietic stem-cell transplant. It is not an approval for knee arthritis, autism, general recovery or longevity. Ryoncil label.
Other jurisdictions have made different, product-specific decisions. China conditionally approved the cord-derived product amimestrocel in January 2025 for patients aged 14 and older with steroid-refractory acute graft-versus-host disease predominantly involving the gut. South Korea’s regulator lists Cartistem, a cord-blood-derived MSC product administered surgically for specified severe knee-cartilage defects. These approvals do not transfer to another manufacturer, route or indication. Chinese regulatory announcement; MFDS Cartistem record.
For any proposed treatment, ask for the actual product and the authorization or clinical-trial pathway in the country where it would be given. A registered study, a licensed facility and an approved medicine are different things.
What have the main clinical trials found?
Graft-versus-host disease: The single-arm pediatric study supporting Ryoncil included 54 children. At day 28, 38 responded, including 16 complete responses. Without a randomized control group, that study does not by itself measure how much benefit the cells added over alternative care. An earlier randomized study of remestemcel-L enrolled 260 patients, including children and adults, and missed its main endpoint: durable complete response was 35% with cells and 30% with placebo, each added to second-line treatment. Favorable subgroup findings did not change the overall result. Pediatric study; Randomized trial.
Knee osteoarthritis: Results include real positive findings as well as negative ones. A placebo-controlled study enrolling 261 people with grade 3 arthritis found greater pain and WOMAC symptom improvement at six months after one injection of culture-expanded cells from the patient’s fat. It did not find a between-group difference in cartilage defects on MRI. Adipose-cell trial.
In MILES, 480 people were randomized and 440 entered the primary analysis. Bone marrow concentrate, adipose stromal vascular fraction and culture-expanded donor cord-tissue MSCs were compared with corticosteroid injection. None was superior for the main pain outcomes at one year, and MRI scores did not improve. The first two preparations were cell mixtures, not the same product as expanded MSCs. A correction restored missing baseline table entries. MILES trial; correction.
ADIPOA2 also found no significant advantage over saline on its six-month responder endpoint: 47.3% with expanded adipose cells versus 54.8% with placebo. It randomized 135 people, but only 97 were analyzed. A much smaller cord-cell study, with 26 participants in its analysis, favored two injections over hyaluronic acid for several pain measures at one year, without an MRI difference. Those results justify further work on particular products and schedules; they do not establish that more injections are generally better. ADIPOA2; Cord-cell study.
Crohn’s perianal fistulas: The first large trial of locally injected adipose-derived darvadstrocel found combined clinical and MRI remission in 50% of the cell group versus 34% of controls at 24 weeks. The confirmatory ADMIRE CD II trial randomized 568 people and found 48.8% versus 46.3%, with no significant difference. Both groups received fistula preparation and closure procedures. The EU authorization was withdrawn in December 2024 because the overall evidence no longer justified continued use; the withdrawal communication did not identify a new safety signal. First trial; Confirmatory trial; EU withdrawal communication.
Neurological conditions: MESEMS randomized 144 people with active multiple sclerosis and found no reduction in its primary MRI measure of inflammatory lesions after intravenous autologous marrow MSCs. In autism, cord-tissue MSCs have been studied, separately from cord-blood infusions. Posted results from the 137-child IMPACT trial did not show a significant advantage on its main six-month communication and socialization measure. Neither result answers every possible product or route, but both matter when setting expectations. MESEMS; IMPACT registry results.
Why the manufacturing details matter
Culture expansion grows selected cells into larger numbers and allows defined manufacturing controls. It does not itself prove that a dose works. Same-day marrow concentrate and stromal vascular fraction contain mixtures of cells and have also been studied in randomized trials. They should be identified accurately, rather than treated as interchangeable with expanded MSCs.
Identity testing asks what the cells are. Viability asks how many are alive under the test conditions. Potency testing measures a relevant biological activity. Sterility and other microbial tests address contamination. One result cannot stand in for all the others. FDA’s November 2026 potency guidance describes a product-specific assurance strategy, not a universal score that predicts benefit for every condition. FDA potency guidance.
A frozen product also needs a defined thawing and handling process. Some clinical products are administered after fresh culture instead. The useful question is how the actual dose was made, released and handled. Our manufacturing article and source comparison explain those distinctions.
What is encouraging, and what remains uncertain?
Encouraging findings
- Specific MSC products have regulatory approvals for defined conditions.
- Some randomized trials show improvements in pain, function or disease response.
- The biology provides several credible mechanisms to investigate.
Limits of the evidence
- Several large controlled trials missed their main endpoint.
- Symptom improvement does not necessarily mean tissue regeneration.
- A finding for one product does not establish the effect of another.
Questions to bring
- What outcome is the treatment expected to change, and by how much?
- Was this product and route tested in people with a similar condition?
- What are the alternatives, follow-up plan and arrangements if a complication occurs?
What about safety and personal experiences?
Safety depends on the product, route, patient and accompanying treatment. Ryoncil’s label warns about hypersensitivity and infusion reactions, possible transmission of infectious agents and ectopic tissue formation. Serious adverse reactions were reported in 35 of its 54 study participants, who had severe underlying illness. That figure is not a risk estimate for a healthy person receiving a different MSC preparation, and it should not be hidden behind a general claim that MSCs are safe. Ryoncil safety information.
A 2026 review of 42 randomized trials involving 2,280 adults receiving intravascular cord-derived MSCs found an increased fever risk. It did not find clear increases in the other pooled safety outcomes, including infection, malignancy and thrombotic events. That is useful reassurance within the studied settings, with limits from small trials, variable reporting and follow-up. It does not establish safety for every cell product or delivery route. Cord-MSC safety review.
A person’s improvement after treatment is worth listening to. It is harder to know what caused it when rehabilitation, medication changes, fluctuating symptoms and expectations occur at the same time. Useful follow-up records the starting problem, the treatment, measurable change and any adverse effects. It should also capture people who do not improve.
Questions people ask
Can MSC injections rebuild cartilage?
Some trials report less pain and better function, but those outcomes are not proof of new cartilage. The positive adipose-cell trial, MILES and the small repeated cord-cell study did not demonstrate the corresponding MRI improvement described in their reports. Adipose-cell trial; MILES; Cord-cell study.
Is MSC therapy approved?
Approval applies to a named product, indication and jurisdiction. Ryoncil is FDA-approved for steroid-refractory acute graft-versus-host disease in children aged two months and older. It is made from donor bone marrow, not umbilical cord. China and South Korea have separate, narrowly defined cord-derived product approvals. Ryoncil label; Chinese announcement; MFDS record.
Are repeated doses better than one?
There is no general answer across MSC products and conditions. A small knee study favored repeated cord-cell injections over hyaluronic acid, but it cannot establish the best schedule for other preparations or diseases. A larger dose or longer course needs its own evidence. Knee trial.
What should I ask about the actual product?
Ask for its name, tissue source, donor relationship, manufacturing method, route and schedule. Request the relevant release tests, including identity, viability, microbial testing and potency. Then ask which human trial supports its use for your condition, what alternatives exist and who will manage follow-up.
The evidence
Selected original studies, registry records and regulatory sources checked November 9, 2026. Study design and access limits are reflected in the discussion above. Explore related records on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Evidence and approvals apply to the products and populations described. Any treatment decision should be made with a qualified physician. Individual results vary.